Roche to buy InterMune for $8.3B

Roche, a Swiss pharmaceutical company, plans to acquire Brisbane, Calif.-based InterMune, a biotech firm, for $8.3 billion, according to a Wall Street Journal report.

Advertisement

Roche largely focuses on cancer and autoimmune-focused diagnostics and treatments. This acquisition will expand Roche’s offering to include InterMune’s respiratory offerings.

More articles on acquisitions:

Cleveland Clinic finalizes Akron General minority ownership deal
Duke LifePoint, Conemaugh Health reach definitive acquisition agreement
Allergan, Salix in potential merger talks

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.